Creutzfeldt-Jacob disease

Authors: Z. Gdovinová
Published in: Cesk Slov Neurol N 2013; 76/109(2): 138-154
Category: Minimonography


Creutzfeldt-Jacob disease (CJD) is a prion disease. Prion diseases are fatal neurodegenerative conditions affecting humans and a wide variety of animals. In prion diseases, normal, cellular protein (PrPC) is converted into insoluble, protease-resistant scrapie prion protein (PrPSC). PrP is encoded by the prion protein gene (PRNP) localised on the short arm of chromosome 20. There are several forms of CJD, sporadic CJD (sCJD), seen in about 85% of patients, being the most common one. Some cases are genetic (gCJD) that occur as a consequence of va­rious mutations (including point mutations, insertions and deletions); when the mutation is present in more than two members of a family, the disease is called familial (fCJD). Remaining two forms, i.e. iatrogenic CJD (iCJD) and variant CJD (vCJD), are acquired. iCJD (now called accidentally transmitted) is acquired through contaminated transplants and instruments. vCJD is a novel form of human prion disease first reported in the United Kingdom in 1996. It is likely that bovine prions from „mad cows“, affected with bovine spongiform encefalopathy (BSE), were passed to humans through consumption of beef products from affected animals.

Key words:
Creutzfeldt-Jacob disease – prion protein – 14-3-3 protein – electroencephalography – magnetic resonance imaging – dementia


1. Budka H, Head MW, Ironside JW et al. Sporadic Creutzfeldt-Jakob disease. In: Dickinson DW, Weller RO (eds). Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Chichester: Blackwell Publishing 2011.

2. Gajdusek DC, Gibbs J, Alpers M. Experimental transmission of Kuru-like syndrome to chimpanzees. Nature 1966; 209(5025): 794–796.

3. Gibbs CJ jr, Gajdusek DC, Asher DM, Alpers MP, Beck E, Daniel PM et al. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968; 161(3839): 388–389.

4. Prusiner SB. The prion diseases. Brain Pathol 1998; 8(3): 499–513.

5. Mitrová E, Wsólová L, Janáková A. Riziko horizontálneho šírenia Creutzfeldtovej-Jakobovej choroby z pohľadu novších poznatkov. Neurol Prax 2007; 3: 155–158.

6. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89(4): 1105–1152.

7. Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Annu Rev Biochem 1998; 67: 793–819.

8. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95(23): 13363–13383.

9. Capellari S, Strammiello R, Saverioni D, Kretzschmar H, Parchi P. Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol 2011; 121(1): 21–37.

10. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull 2003; 66: 213–139.

11. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39(6): 767–778.

12. Head MW, Ironside JW. Review: Creutzfeldt-Jakob disease: prion protein type, disease phenotype and agent strain. Neuropathol Appl Neurobiol 2012; 38(4): 296–310.

13. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and aetiology of „new variant“ CJD. Nature 1996; 383(6602): 685–690.

14. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 1996; 274(5295): 2079–2082.

15. Appleby BS, Zerr I. Sporadic Creutzfeldt-Jakob disease: changes not only in the brain? Neurology 2012; 79(10): 965–966.

16. Mastrianni J. The genetics of prion diseases. Genet Med 2010; 12(4): 187–195.

17. Ironside JW, Knight RS, Head MW. Iatrogenic Creutz­feldt-Jakob disease. In: Dickinson DW, Weller RO (eds). Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Chichester: Blackwell Publishing 2011: 381–386.

18. Rusina R, Matěj R. Prionová onemocnění. Neurol Prax 2012; 13(2): 80–84.

19. Comoy EE, Casalone C, Lescoutra-Etchegaray N, Zanusso G, Freire S, Marcé D et al. Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PLoS One 2008; 3(8): e3017.

20. Béringue V, Herzog L, Reine F, Le Dur A, Casalone C, Vilotte JL et al. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis 2008; 14(12): 1898–1901.

21. Kong Q, Zheng M, Casalone C, Qing L, Huang S, Chakraborty B et al. Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 2008; 82(7): 3697–3701.

22. Ward HJ, Everington D, Cousens SN, Smith-Bathgate B, Gillies M, Murray K et al. Risk for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008; 63(3): 347–354.

23. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337(8755): 1441–1442.

24. Global surveillance, diagnosis, and therapy of human Transmissible Spongiform Encephalopaties: report of a WHO consultation. Geneva, Switzerland, 9–11 February 1998. Available from:

25. WHO manual for surveillance of human transmissible spongiform encephalopathies including variant Creutzfeldt-Jakob disease. Geneva, Switzerland 2003. Available from:

26. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heineman U et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132(Pt10): 2659–2668.

27. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46(2): 224–233.

28. Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P et al. Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 2012; 124(4): 517–529.

29. Parchi P, Strammiello R, Notari S, Giese A, Langeveld JP, Ladogana A et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotypes and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol 2009; 118(5): 659–671.

30. Cali I, Castellani R, Yuan J, Al-Shekhlee A, Cohen ML, Xiao X et al. Classification of sporadic Creutzfeldt-Jakob disease revisited. Brain 2006; 129(Pt 9): 2266–2277.

31. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11(7): 618–628.

32. Budka H, Head MW, Ironside JW et al. Sporadic Creutzfeldt-Jakob disease. In: Dickinson DW, Weller RO (eds). Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Chichester: Blackwell Publishing 2011: 325–335.

33. Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129(Pt9): 2278–2287.

34. Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72(23): 1994–2001.

35. Collie DA, Summers DM, Sellar RJ, Ironside JW, Cooper S, Zeidler M et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol 2003; 24(8): 1560–1569.

36. Lukic A, Mead S, Rudge P, Collinge J. Comment on validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol 2011; 69(1): 212.

37. Krasnianski A, Schulz-Schaeffer WJ, Kallenberg K, Meissner B, Collie DA, Roeber S et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 2006; 129(Pt 9): 2288–2296.

38. Krasnianski A, Meissner B, Schulz-Schaeffer WJ, Kallenberg K, Bartl M, Heinemann U et al. Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2006; 63(6): 876–880.

39. Sheardova K, Matej R, Rektorova I. Steroid-responsive hyperintense lesions in a patient with Creutzfeldt-Jakob disease. Cesk Slov Neurol N 2010; 73/106(1): 76–79.

40. Seipelt M, Zerr I, Nau R, Mollenhauer B, Kropp S, Steinhoff BJ et al. Hashimotoʼs encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1999; 66(2): 172–176.

41. Haïk S, Brandel JP, Sazdovitch V, Delasnerie-Lauprêtre N, Peoch K, Laplanche JL et al. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 2000; 55(9): 1401–1404.

42. Ladogana A, Sanchez-Juan P, Mitrová E, Green A, Cuadrado-Corrales N, Sánchez-Valle R et al. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol 2009; 256(10): 1620–1628.

43. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 2033; 60(6): 813–816.

44. Matěj R, Rusina R, Koukolík F. 5 let činnosti Národní referenční laboratoře lidských prionových onemocnění při Oddělení patologie a molekulární medicíny FTNsP: naše zkušenosti a přehled literatury. Cesk Slov Neurol N 2007; 70/103(6): 637–642.

45. Mitrová E. Contribution of CSF biomarkers to the early diagnosis of human genetic transmissible spongiform encephalopathies. ENJ 2012; 4(1): 9–14.

46. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55(6): 811–815.

47. Gmitterová K, Heinemann U, Bodemer M, Krasnianski A, Meissner B, Kretzschmar HA et al. 14-3-3 levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 2009; 30(11): 1842–1850.

48. Chohan G, Pennington C, Mackenzie JM, Andrews M, Everington D, Will RG et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the dia­gnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry 2010; 81(11): 1243–1248.

49. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67(4): 637–643.

50. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011; 17(2): 175–178.

51. Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol 2004; 56(5): 702–708.

52. Richardson EP Jr, Masters CL. The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrPCJD in the nervous system. Brain Pathol 1996; 5(1): 33–41.

53. Budka H, Aguzzi A, Brown P, Brucher JM, Bugia­­ni O, Gullotta F et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopaties (prion diseases). Brain Pathol 1995; 5(4): 459–466.

54. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53(9): 913–920.

55. Parchi P, Gambetti P, Capellari S. Genetic Creutzfeldt-Jakob disease. In: Dickinson DW, Weller RO (eds). Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Chichester: Blackwell Publishing 2011: 336–345.

56. Hsiao K, Meiner Z, Kahana E, Cass C, Kahana I, Avrahami D et al. Mutation of the prion protein in Libyan Jews with Creutzfeldt-Jakob disease. N Engl J Med 1991; 324(16): 1091–1097.

57. Goldfarb LG, Mitrova E, Brown P, Toh BK, Gajdusek DC. Mutation in codon 200 of scrapie amyloid protein gene in two clusters of Creutzfeldt-Jakob disease in Slovakia. Lancet 1990; 336(87): 514–515.

58. Neufeld MY, Josiphov J, Korczyn AD. Demyelinating peripheral neuropathy in Creutzfeldt-Jakob disease. Muscle Nerve 1992; 15(11): 1234–1239.

59. Antoine JC, Laplanche JL, Mosnier JF, Beaudry P, Chatelain J, Michel D. Demyelinating peripheral neuropathy with Creutzfeldt-Jakob disease and mutation at codon 200 of the prion protein gene. Neurology 1996; 46(4): 1123–1127.

60. Hainfellner JA, Parchi P, Kitamoto T, Jarius C, Gambetti P, Budka H. A novel phenotype in familial Creutzfeldt-Jakob disease: prion protein gene E200K mutation coupled with valine at codon 129 and type 2 protease-resistant prion protein. Ann Neurol 1999; 45(6): 812–816.

61. Goldfarb LG, Petersen RB, Tabaton M, Brown P, LeBlanc AC, Montagna P et al. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. Science 1992; 258(5083): 806–808.

62. Matej R, Kovacs GG, Johanidesova S, Keller J, Matejckova M, Novakova J et al. Genetic Creutzfeldt-Jakob disease with R208H mutation presenting as progressive supranuclear palsy. Mov Disord 2012; 27(4): 476–479.

63. Brown P, Goldfarb LG, Kovanen J, Haltia M, Cathala F, Sulima M et al. Phenotypic characteristics of familial Creutzfeldt-Jakob disease associated with the codon 178Asn PRPNP mutation. Ann Neurol 1992; 31(3): 282–285.

64. Rusina R, Fiala J, Holada K, Matějčková M, Nováková J, Ampapa R et al. Gerstmann-Sträussler-Scheinker syndrome with the P102L pathogenic mutation presenting as familial Creutzfeldt-Jakob disease: a case report and review of the literature. Neurocase 2013; 19(1): 41–53.

65. Ironside JW, Head MW, Will RG. Variant Creutzfeldt-Jakob disease. In: Dickinson DW, Weller RO (eds). Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd ed. Chichester: Blackwell Publishing 2011: 354–363.

66. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347(9006): 921–925.

67. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363(9407): 417–421.

68. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 2006; 368(9552): 2061–2067.

69. Mitrová E. Creutzfeldtova-Jakobova choroba: riziká, výskyt a možnosti diagnostiky najvýznamnejšej prenosnej demencie. Neurol Prax 2004; 1: 29–32.

70. World Health Organization. The revision of the surveillance case definition for variant Creutzfeldt-Jakob disease (vCJD). Available from:

71. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens SN et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000; 47(5): 575–582.

72. Summers DM, Collie DA, Zeidler M, Will RG. The pulvinar sign in variant Creutzfeldt-Jakob disease. Arch Neurol 2004; 61(3): 446–447.

73. Yamada M, Variant CJD Working Group, Creutzfeldt-Jakob Disease Surveillance Committee, Japan. The first Japanese case of variant Creutzfeldt-Jakob disease showing periodic elektroencephalogram. Lancet 2006; 367(9513): 874.

74. Binelli S, Agazzi P, Giaccone G, Will RG, Bugiani O, Franceschetti S et al. Periodic elektroencephalogram complexes in a patient with variant Creutzfeldt-Jakob disease. Ann Neurol 2006, 59(2): 423–427.

75. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon W, Samad S et al. Peripheral tissue involvement in sporadic, iatrogenic and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative and bio­chemical study. Am J Pathol 2004; 164(1): 143–153.

76. Brown P, Brandel JP, Preece M, Sato T. Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 2006; 67(8): 389–393.

77. Jirsova K, Krabcova I, Novakova J, Hnathova I, Koukolik F, Kubesova B et al. The assessment of pathogenic prions in the brains of eye tissue donors: 2-years experience in the Czech Republic. Cornea 2010; 29(9): 996–999.

78. Mitrova E, Cernak A, Slivarichova D, Koscova S, Bernovska V, Cernak M. Experience with preventive genetic testing of corneal donors in Slovakia. Cornea 2011; 30(9): 987–990.

79. Heath CA, Barker RA, Esmonde TF, Harvey P, Roberts R, Trend P et al. Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry 2006; 77(7): 880–882.

80. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55(8): 1075–1081.

81. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive dementia. Ann Neurol 2008; 64(1): 97–108.

82. Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. Neurologist 2007; 13(3): 140–147.

83. Lawn ND, Westmoreland BF, Kiely MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clinic Proc 2003; 78(11): 1363–1368.

84. Doležalová I, Kuba R, Musilová K, Kašpárek T, Brázdil M, Rektor I. Neparaneoplastická limbická encefalitida s pozitivitou anti-LGI1 protilátek. Neurol Prax 2012; 13(3): 221–224.

85. Zborníková P, Krasulová E, Bušek P, Nytrová P, Peterová V, Špačková N et al. Autoimunitní limbická encefalitida asociovaná s LGI1 protilátkami. Neurol Prax 2012; 13(6): 350–353.

86. Thieben MJ, Lennon VA, Boeve BF, Aksamit AJ, Keegan M, Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004; 62(7): 1177–1182.

87. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127(Pt 3): 701–712.

88. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61(1): 25–36.

89. Castillo P, Woodruff B, Caselli R, Vemino S, Lucchinetti C, Swanson J et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol 2006; 63(2): 197–202.

90. Salvarani C, Brown RD Jr, Calamia KT, Christianson TJ, Weigand SD, Miller DV et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62(5): 442–451.

91. Amara AW, Bashir K, Palmer CA, Walker HC. Challenges in diagnosis of isolated central nervous system vasculitis. Brain Behav 2011; 1(1): 57–61.

92. Bushara KO. Neurologic presentation of celiac disease. Gastroenterology 2005; 128 (4 Suppl 1): S92–S97.

93. Itzhaki RF, Wozniak MA. Viral infection and cognitive decline. J Am Geriatr Soc 2007; 55(1): 131.

94. Almeida OP, Lautenschlager NT. Dementia asso­ciated with infectious diseases. Int Psychogeriatr 2005; 17 (Suppl 1): S65–S77.

95. Timmermans M, Carr J. Neurosyphylis in the modern era. J Neurol Neurosurg Psychiatry 2004; 75(12): 1727–1730.

96. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 2008; 70(13): 992–1003.

97. Kennedy PG. Human African trypanosomiasis-neurological aspects. J Neurol 2006; 253(7): 411–416.

98. Josephson SA, Papanastassiou AM, Berger MS, Barbaro NM, McDermott MW, Hilton JF et al. The dia­gnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg 2007; 106(1): 72–75.

99. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 2002; 59(10): 1557–1562.

100. Menendez Calderon MJ, Segui Riesco ME, Argüelles M, Nuño Mateo J. Intravascular lymphomatosis. A report of three cases. An Med Interna 2005; 22(1): 31–34.

101. Schott JM, Reiniger L, Thom M, Holton JL, Grieve J, Brandner S et al. Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathol 2010; 120(3): 327–341.

102. Kratochvílová J. Doporučený pracovní postup pro ošetřování pacientů s podezřením na CJN, nvCJN a režim dekontaminace a sterilizace. Available from: www.sneh/cz/.

103. Koukolík F. Pitvy a bioptická vyšetření mozku při podezření na prionové choroby. Available from:

104. Mitrová E. Transmissibilné spongioformné encefalopatie. Prionové choroby. Budapešť Press Publica 1999.

105. Zerr I. Therapeutic trials in human transmissible spongiform encephalopaties: recent advances and problems to address. Infect Disord Drug Targets 2009; 9(1): 92–99.

106. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52(4): 503–506.

107. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004; 62(5): 714–718.

108. Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Inf Disord Drug Targets 2009; 9(1): 23–30.

109. Rusina R, Rusinová K, Holmerová I, Šimek J. Léčba pokročilé demence – paliativní přístup. Neurol Prax 2010; 11: 16–19.

110. Koukolík F. Lidská prionová onemocnění jsou v ČR pod kontrolou už 10 let. Available from:

Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 2

2013 Issue 2

Most read in this issue

This topic is also in:

Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account